Q3 2019 EPS Estimates for Zynex Inc. (OTCMKTS:ZYXI) Decreased by Analyst

Share on StockTwits

Zynex Inc. (OTCMKTS:ZYXI) – Research analysts at B. Riley lowered their Q3 2019 earnings estimates for Zynex in a report released on Wednesday, May 1st, Zacks Investment Research reports. B. Riley analyst M. Wiesenberger now anticipates that the company will post earnings of $0.06 per share for the quarter, down from their previous forecast of $0.07. B. Riley has a “Buy” rating on the stock. B. Riley also issued estimates for Zynex’s Q4 2019 earnings at $0.07 EPS.

Several other research firms also recently weighed in on ZYXI. Zacks Investment Research upgraded shares of Zynex from a “hold” rating to a “buy” rating and set a $5.50 price target on the stock in a research report on Saturday, March 2nd. ValuEngine upgraded shares of Zynex from a “hold” rating to a “buy” rating in a research report on Friday, February 8th.

ZYXI traded down $0.08 during trading on Thursday, hitting $7.44. The company’s stock had a trading volume of 76,738 shares, compared to its average volume of 68,204. Zynex has a one year low of $2.40 and a one year high of $8.00. The company has a market capitalization of $242.48 million, a PE ratio of 33.82 and a beta of 1.05.

Zynex (OTCMKTS:ZYXI) last issued its earnings results on Tuesday, April 30th. The company reported $0.07 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.05 by $0.02. Zynex had a net margin of 33.33% and a return on equity of 152.81%. The company had revenue of $9.20 million for the quarter, compared to analysts’ expectations of $8.45 million.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Acadian Asset Management LLC purchased a new position in shares of Zynex in the 1st quarter worth $215,000. WealthTrust Axiom LLC purchased a new position in shares of Zynex in the 1st quarter worth $132,000. O Shaughnessy Asset Management LLC purchased a new position in shares of Zynex in the 1st quarter worth $118,000. Sigma Planning Corp purchased a new position in shares of Zynex in the 1st quarter worth $63,000. Finally, ExodusPoint Capital Management LP purchased a new position in shares of Zynex in the 1st quarter worth $45,000. 0.05% of the stock is owned by institutional investors.

In related news, CEO Thomas Sandgaard sold 15,403 shares of the firm’s stock in a transaction on Wednesday, May 15th. The shares were sold at an average price of $7.50, for a total transaction of $115,522.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Daniel J. Moorhead sold 25,000 shares of the firm’s stock in a transaction on Monday, May 13th. The shares were sold at an average price of $7.17, for a total transaction of $179,250.00. The disclosure for this sale can be found here. Insiders have sold a total of 380,487 shares of company stock worth $2,181,725 over the last 90 days.

Zynex Company Profile

Zynex, Inc, a medical technology company, designs, manufactures, and markets electrotherapy medical devices used for pain management and rehabilitation. Its products include NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation device; NeuroMove, an electromyography triggered electrical stimulation device; and InWave, an electrical stimulation product for the treatment of female urinary incontinence.

Featured Article: What is Elliott Wave theory?

Get a free copy of the Zacks research report on Zynex (ZYXI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Zynex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynex and related companies with MarketBeat.com's FREE daily email newsletter.